Caladrius Biosciences, Inc. (CLBS) Given Buy Rating at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Caladrius Biosciences, Inc. (NASDAQ:CLBS) in a report published on Friday. HC Wainwright currently has a $7.00 price objective on the biotechnology company’s stock.
Several other equities analysts have also recently weighed in on CLBS. Zacks Investment Research raised shares of Caladrius Biosciences from a hold rating to a buy rating and set a $4.25 price target on the stock in a research report on Tuesday, September 26th. ValuEngine raised shares of Caladrius Biosciences from a strong sell rating to a sell rating in a research report on Friday, September 1st.
Shares of Caladrius Biosciences (NASDAQ CLBS) traded down $0.12 during midday trading on Friday, reaching $3.01. 25,300 shares of the company traded hands, compared to its average volume of 59,040. Caladrius Biosciences has a twelve month low of $2.63 and a twelve month high of $7.79.
Caladrius Biosciences (NASDAQ:CLBS) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.38) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.79) by $0.41. Caladrius Biosciences had a negative net margin of 84.10% and a negative return on equity of 141.14%. equities analysts expect that Caladrius Biosciences will post -2.73 earnings per share for the current year.
Institutional investors have recently bought and sold shares of the business. KCG Holdings Inc. lifted its position in shares of Caladrius Biosciences by 74.6% during the 1st quarter. KCG Holdings Inc. now owns 36,291 shares of the biotechnology company’s stock worth $183,000 after buying an additional 15,501 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Caladrius Biosciences by 34.3% during the 1st quarter. Renaissance Technologies LLC now owns 97,552 shares of the biotechnology company’s stock worth $491,000 after buying an additional 24,900 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Caladrius Biosciences by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 155,380 shares of the biotechnology company’s stock worth $723,000 after buying an additional 4,163 shares in the last quarter. 6.47% of the stock is currently owned by hedge funds and other institutional investors.
About Caladrius Biosciences
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
Receive News & Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.